Verve Therapeutics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2014	FY 2013
Period Ending	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013
Revenue	10,599	7,107
Revenue Growth (YoY)	49.14%	-
Cost of Revenue	4,885	3,456
Gross Profit	5,714	3,651
Selling, General & Admin	2,842	2,744
Research & Development	547.84	474.07
Other Operating Expenses	59.69	51.27
Operating Expenses	3,659	2,218
Operating Income	2,055	1,433
Interest Expense	-92.04	-133.02
Interest & Investment Income	22.54	7.94
Currency Exchange Gain (Loss)	121.13	-19.67
Other Non Operating Income (Expenses)	50.22	-209.94
EBT Excluding Unusual Items	2,157	1,078
Gain (Loss) on Sale of Investments	-	18.5
Gain (Loss) on Sale of Assets	11.36	66.04
Other Unusual Items	-	-149.71
Pretax Income	2,168	1,013
Income Tax Expense	190.13	121.1
Net Income	1,978	891.91
Net Income to Common	1,978	891.91
Net Income Growth	121.80%	-
Shares Outstanding (Basic)	2	1
Shares Outstanding (Diluted)	2	1
Shares Change (YoY)	14.24%	-
EPS (Basic)	1229.00	633.00
EPS (Diluted)	1229.00	633.00
EPS Growth	94.16%	-
Free Cash Flow	-254.34	-534.55
Free Cash Flow Per Share	-158.01	-379.37
Gross Margin	53.91%	51.37%
Operating Margin	19.39%	20.16%
Profit Margin	18.66%	12.55%
Free Cash Flow Margin	-2.40%	-7.52%
EBITDA	2,761	2,217
EBITDA Margin	26.05%	31.20%
D&A For EBITDA	705.45	784.37
EBIT	2,055	1,433
EBIT Margin	19.39%	20.16%
Effective Tax Rate	8.77%	11.95%
Advertising Expenses	294.04	320.56

Source: S&P Global Market Intelligence. Standard template. Financial Sources.